Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.

Chung, Suyoun; Kijima, Kyoko; Kudo, Aiko; Fujisawa, Yoshiko; Harada, Yosuke; Taira, Akiko; Takamatsu, Naofumi; Miyamoto, Takashi; Matsuo, Yo; Nakamura, Yusuke

Chung, Suyoun; Kijima, Kyoko; Kudo, Aiko; Fujisawa, Yoshiko; Harada, Yosuke; Taira, Akiko; Takamatsu, Naofumi; Miyamoto, Takashi; Matsuo, Yo; Nakamura, Yusuke.

Afiliação

Chung S; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Kijima K; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Kudo A; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Fujisawa Y; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Harada Y; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Taira A; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Takamatsu N; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Miyamoto T; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Matsuo Y; OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan.
Nakamura Y; Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA.

Oncotarget ; 11(41): 3749-3750, 2020 Oct 13.

Article em En | MEDLINE | ID: mdl-33110482

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google